Merck & Co (MRK)

When choosing dividend ETFs, diversification is a top priority.

A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself.

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

The healthcare sector outperformed the rest of the market over the past week.

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. ...

Investors can find much better opportunities.

A lucrative dividend will always attract investors when times are rocky.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

They can weather many storms.

Mounjaro generated $8.66 billion in sales in the first quarter.

Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent pro...

Tempus AI (TEM) Q1 2026 Earnings Transcript

It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term cash flow.

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co...